Sustained Benefit of Blinatumomab in Infants With <i>KMT2A</i>-Rearranged ALL: Long-Term Outcomes, Toxicity, and Pharmacokinetics.

ABSTRACT: KMT2A-rearranged infant ALL (KMT2A-r ALL) has a poor prognosis. Adding blinatumomab, a bispecific T-cell engager targeting CD19, to standard chemotherapy for infants with KMT2A-r ALL improved short-term outcomes. Here, we present long-term results, toxicity, and pharmacokinetics of blinatumomab from this study. Thirty infants received Interfant-06 protocol chemotherapy with one additional postinduction blinatumomab course. Disease-free survival (DFS) and overall survival (OS) were compared with a historical Interfant-06-selected cohort without blinatumomab. Infection and administration of intravenous immunoglobulin (IVIg) and granulocyte-colony stimulating factor (G-CSF) were documented. Blinatumomab's steady-state concentration (Css) and clearance (CL) were analyzed.

SUBMITTER: Vieira Martins M 

PROVIDER: S-EPMC12879164 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature